Equibles does not estimate personal net worth.
Get an email with a short summary when Tg Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get TGTX alertsMichael (Mike) Weiss is recorded as CEO at Tg Therapeutics, Inc. (TGTX). Michael (Mike) Weiss has spoken on 3 earnings calls and 1 other investor event across 1 company, most recently for Tg Therapeutics, Inc. on November 9, 2026. Tg Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Tg Therapeutics, Inc. includes Michael S. Weiss (CEO and Board Member), Sean A. Power (CFO), Daniel Hume (Board Member) and 7 others.
“I'm pleased to report another strong quarter for TG, with meaningful progress across both our commercial business and development programs. Global revenue for the quarter was approximately $260 million, including $233 million in U.S. Breambe net revenue.”
“Our projections for this year are year-end. U.S. only is $885 to $900 million, so sales are going well. We're just in the early phases, really, of tapping into this market.”
“The first quarter of 2026 was, in my view, exceptional, not because of any single milestone, but because of the consistency and durability we're now seeing across the business.”
“2025 was a defining year for TG Therapeutics. We didn't just grow, we scaled, we strengthened, and we demonstrated that Briandvi is becoming a foundational therapy in relapsing multiple sclerosis.”
Biotechnology · Healthcare
CEO
